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============

The transdermal route, in many clinical implications, is used to avoid the decisive limitations associated with the oral drug delivery methods \[[@CR1]\]. The recent developments in this area highlight the utility of microneedle array (MN) systems in delivering drugs transdermally that are unable to diffuse through skin by passive diffusion or by external source-assisted diffusion \[[@CR2]\]. MN has been proved as a convenient technique in delivering molecules of high molecular mass. Moreover, it is designed to keep one away from the pain-related issues while being injected with the hypodermic needles \[[@CR3]\]. Here, we present the current scenario, the applications, and the recent advances in the delivery of molecules by microneedle array technique. Various ways have been explored to deal with the limited potency of a therapeutic agent. Consequently, future research will concentrate on creating techniques to diminish loss during preparing and stacking just as improving the structures of microneedles to guarantee better medication transport to make microneedle-based treatment more affordable, especially for developing countries. Though the investigations on microneedle-based drug delivery systems are expanding every year, the shortcomings associated with these systems should carefully be addressed. This would let microneedles pass the clinical pertinence and help reach to the potential market. Some of the microneedle-based drug delivery systems have entered in phase III clinical trials. However, the clinical pertinence of microneedle in vaccination is yet to be proved \[[@CR4], [@CR5]\]. Therefore, efforts that are being made to deliver the drug by microneedle array technique have placed them to the next level and eventually become recognized as a strong alternative to the hypodermic needles. This review highlights the applications, recent advances, and clinical pertinence of these systems in transdermal delivery of the drugs for potential therapeutic and safety benefits.

Transdermal Drug Delivery and Beyond {#Sec2}
====================================

The global drug delivery market has been observed as large as 440.5 billion USD in 2018. Considering cost-effectiveness, bioavailability, and quick action, injectables are known to be very efficient. These systems have immensely been used in the delivery of biological macromolecules, insulin, vaccines, and dots. However, their invasive nature, stability issues, and noncompliance have always been the issues of concern and led to the requirement of highly skilled medical practitioners for administration \[[@CR6]\]. Some of the measures have been taken into consideration to replace all such needles; however, necessary improvement could not be made. The history of conventional transdermal drug delivery systems is almost five decades old. Several drugs, viz. testosterone, nicotine, selegiline, and clonidine, have been delivered successfully by these systems. These types of drug delivery systems proved to be a patient-friendly, effective, and painless techniques. However, the longer onset of action, restriction of delivering only molecules of smaller molecular weight and lipophilicity limited their utility in the delivery of most of the critical macromolecules. Penetration enhancers, iontophoresis, and sonophoresis techniques could solve the purpose up to some extent, but efficient delivery of the drugs in compliance with the patients was a major concern. The application of microneedle has now been widely investigated, and these technologies are being developed specifically for the delivery of biological macromolecules, insulin, growth hormones, immunobiological, proteins, siRNA, and peptides \[[@CR7]\]. When studied in terms of the success rate of the microneedle technologies in clinical trials reaching the global market, these have been found to show immense potential to transform the global transdermal market.

Micro-Needle Patches {#Sec3}
====================

The micro-needle**s** are so tiny to see from the naked eye, in fact, less than one millimeter in height \[[@CR8]\]. This micron-sized needle punctures the stratum corneum (the layer of skin that provides the larger barrier for the diffusion of the actives) and creates the pathway that allows the drug molecule to diffuse directly beneath the skin much more quickly. MN was firstly conceptualized in 1970s by Martin S. Gerstel and Virgil A. Place \[[@CR9]\]. The report was published in the late 90s \[[@CR10]\] where it was used as a drug delivery device for percutaneous administeration of a drug directly to the dermis layer and to produce a local and systemic pharmacological effect. In addition to its painless behavior, it has been used to improve the bioavailability of proteinaceous drugs \[[@CR11]\]. MNs have made the delivery of even very complex molecules, like protein, vaccines, and peptides, possible through the transdermal route. Microneedle can be of different types, such as solid, hollow, coated, and dissolving; however, all types of MNs are ultimately used to achieve fast and efficient drug delivery \[[@CR12]\]. In every type of microneedles, needle length is to be adjusted appropriate enough to penetrate the SC and not to puncture nerve endings. If it does not puncture a nerve ending, no pain will be observed at the site. Additionally, these systems have the ability to control the release of the drug and provide safe administration as compared to that of the surgical implantation \[[@CR13]\]. However, it has some disadvantages like the requirement of the sophisticated fabrication process in which preparation of primary mold is required for the development of the MN patch. Mold is normally prepared with the help of polydimethylsiloxane (PDMS) and resins \[[@CR14], [@CR15]\]. If the silicon present in PDMS is left with the needle, it may create skin problems, such as skin irritation and local inflammation. Also, the cost of this technology could be high \[[@CR16]\] and the dose accuracy may be less as compared to that of the hypodermic needles. Preferably, very less amount of drugs can be loaded into or coated over the microneedle tips; therefore, drugs with a low dose (few milligram per kilogram body weight) are preferred. MN should be used carefully to avoid particles "bouncing off" the skin surface. In the case when the device is not held vertically, the dose may escape or can penetrate the skin to differing degrees \[[@CR17]\].

Ideal Characteristics of Microneedle Patch {#Sec4}
------------------------------------------

The length or height range of microneedle is varied between 50 to 900 μm and 1 μm in diameter \[[@CR8], [@CR13]\]. The developed MNs must be capable of deep insertion into the skin without breaking. MNs should have an optimum size. These must be able to withstand the insertion force about 10 N and should have proper mechanical stability \[[@CR18]\]. These are also developed for controlled delivery of the drugs with a predetermined rate. These should be able to provide a quick onset of action and efficient drug delivery much like a hypodermic needle. These are developed to enhance **s**elf-medication and facilitate personalized medication at different dose levels \[[@CR19]\]. The durability of these products needs to be more, and these should be leak-proof while delivering drugs of a liquid state. Adherence of these patches needs to be good or as similar to regular transdermal patches.

Polymer Used in Microneedle Formulation {#Sec5}
---------------------------------------

In microneedle manufacturing, the major factor that is considered is the strength of the needle because microneedle must get inserted into the epidermal layer without breaking for proper delivery of the drug \[[@CR18]\]. The size and shape of microneedles are also essential, along with the sharpness of the tip of the needle. In addition, the biocompatibility of the needles with the biosystem is also very critical \[[@CR20]\]. Therefore, polymer selection for the development of microneedles is very crucial. The ideal polymer should be biocompatible and must be able to provide sufficient mechanical strength to the microneedles \[[@CR21]\]. Ingredients used for the preparation of microneedles include glass, silicone, and metals, such as stainless steel, titanium, solid or coat of gold over nickel, palladium, cobalt, platinum, synthetic, and natural polymers. Some of the materials that have been used and reported for the development of microneedles are listed in Table [1](#Tab1){ref-type="table"}.Table 1List of ingredients used for the preparation of microneedleMetalsBiodegradable polymersNon-biodegradable polymersNatural polymersSilliconTitaniumStainless steelSiliconPalladiumPLGAPLAPVPPolyglycolic acidPolycarbonatePolyvinylpyrrolidoneAlginic acidGantrez AN-139Polyvinyl acetatePolyvinyl alcohol (PVA)Carbopol 971 P-NFPolyetherimideZeinChitosanThermoplastic starchCarboxymethyl celluloseAmylopectineDextranGalactoseMaltoseChondroitin sulfate

Applications of Microneedle Array Technique in Transdermal Drug Delivery {#Sec6}
========================================================================

The development of a microneedle array has gained momentum and now become the area of prime research. As much as 2569 research papers have been retrieved until now (from 2000 to 2019) from PubMed using the search term "microneedle." Other databases, like Scopus and Google Scholar, have also been used for the same. Year-wise trends in microneedle development for drug delivery can be seen in Fig. [1](#Fig1){ref-type="fig"}. Single entry was made for one research work. Conference proceedings were excluded. These technologies are being developed for delivering biotherapeutics, biomacromolecules, like insulin, growth hormones, immunobiological, proteins, and peptides. Insulin-loaded dissolvable microneedle of starch and gelatin and bovine serum albumin microneedles are some of the very explicit examples \[[@CR22]\]. Vaccine delivery by the microneedle technology is meant to replace hypodermic needle for avoiding site-specific pain. Kommareddy et al. investigated influenza subunit vaccine-coated microneedle patches for their elicit comparable immune responses with intramuscular injections in guinea pigs \[[@CR23]\]. A very new investigation made recently by Kim et al. \[[@CR24]\] reports the recombinant coronavirus vaccine delivery through skin with the help of microneedle technology for the treatment of COVID-19. This technology helped deliver SARS-CoV-2 S1 subunit vaccines that elicited potent antigen-specific antibody responses that were evident beginning 2 weeks after immunization, and their studies supported the clinical development of MN-based recombinant protein subunit vaccines against SARS, MERS, COVID-19, and other emerging infectious diseases \[[@CR24]\]. For ocular drug delivery, the microneedle-based approaches have been observed to be more effective than topical application. Patel et al. successfully tested suprachoroidal drug delivery to the back of the eye using hollow microneedle \[[@CR25]\]. Microneedle has also been used for local anesthesia. In an investigation, Baek et al. \[[@CR26]\] suggested the use of microneedles in pain-free and rapid local anesthesia. They developed lidocaine coated microneedle that showed in vitro skin penetration and enhanced delivery of the drug in a very short duration, i.e., in 2 min \[[@CR26]\]. For pain management, meloxicam-loaded polymeric microneedles have also been prepared using polydimethylsiloxane molds. The in vitro release studies showed approximately 100% drug release in 60 min. The drug deposition was found to be 63.37%, and transdermal flux was observed to be 1.60 μg/cm^2^/h. Improvement in the skin permeation was found to be increased up to 2.58-folds as compared to that of the free drug solution \[[@CR27]\]. Delivery of chemotherapeutic agents has also been successfully investigated. Bhatnagar et al. \[[@CR28]\] investigated the delivery of chemotherapeutic agents, i.e., tamoxifen and gemcitabine, with the help of microneedles for the treatment of breast cancer. The localized delivery of these drugs helped reduce the side effects \[[@CR28]\]. Xu et al. \[[@CR29]\] reported a microneedle patch-mediated treatment of bacterial biofilms. They report a patch microneedle treatment for the successful removal of biofilms by penetrating the biofilm and delivering antibiotics directly to regions of active growth. They developed chloramphenicol (CAM)-bearing and gelatinase-sensitive gelatin nanoparticle (CAM @ GNP)-filled patches with self-dissolving microneedles and needle tips. Finally, they concluded that for treatment of *Vibrio vulnificus*, biofilm microneedle-mediated treatment is more effective than the drug in free solution \[[@CR29]\]. Neuropathic pain caused by nerve injury is difficult to treat because current systemic pharmacological therapies produce limited pain relief and have undesirable side effects, while current local anesthetics tend to nonspecifically block both sensory and motor functions. Xie et al. \[[@CR30]\] developed analgesic microneedle patch (AMN) for neuropathic pain therapy, and they reported that AMN patches transdermally delivered calcitonin gene-related peptide (CGRP) antagonist peptide in a painless manner, producing effective and safe analgesia on neuropathic pain models, including spared nerve injury (SNI), diabetic neuropathy, and neurogenic inflammatory pain induced by UV radiation in rats \[[@CR30]\]. It has also been used in combination with electroporation, iontophoresis, and other methods to give synergistic effects. Figure [2](#Fig2){ref-type="fig"} shows various applications of microneedles. Additionally, MN research has been expanded from bench scale to pilot or industrial scale for societal benefits. MN-based clinical trials show a complete picture of the overall scenario and that can be seen in Table [2](#Tab2){ref-type="table"}. As a next step, various MN-based pharmaceutical products with different therapeutic benefits are available in the market (Table [3](#Tab3){ref-type="table"}). MNs have emerged as extra prominent within the past decade. The use of MNs as a way for the delivery of medication has to turn out to be a greater appealing method as it overcomes many disadvantages of hypodermic needles, transdermal patches, and other conventional dosage forms \[[@CR31]\]. Therefore, it is essential to look at patents that have been filed within the last decade to correlate the trends of MNs. Table [4](#Tab4){ref-type="table"} depicts the list of some of the very useful patents that have been filled on microneedle technologies, therapeutically active molecules delivered by microneedle technology, and methods of MN fabrication technologies. All these empirical evidences show an encouraging trend in the development of MN-based technologies of therapeutic purposes.Fig. 1Year wise (from 2000 to 2019) trend in MN array-based researchFig. 2Applications of microneedle array in transdermal drug deliveryTable 2Status of clinical trials based on MN techniqueNCT No.ConditionDrugPhaseLocationStatusNCT00837512Type 1 DMInsulin23Eric Felner, MD, MSCR, Emory UniversityCompletedNCT03054480Primary axillary hyperhidrosisBotulinum toxin type ANAThep Chalermchai, Mae Fah Luang, University HospitalCompletedNCT03607903PainAdalimumab ID, Adalimumab SC12Centre for Human Drug Research, NetherlandsActiveNCT01812837Actinic keratosisAminolevulinic acidNAUniversity of California, DavisCompletedNCT03203174HyperhidrosisBotulinum toxin type A1University of California, DavisCompletedNCT01789320Uveitis, intermediate uveitis, posterior uveitis, panuveitis, noninfectious uveitisTriamcinolone acetonide (Triesence®)12Clearside Biomedical, Inc.CompletedNCT02594644Keratosis, actinicAminolevulinic acidNAUniversity of California, DavisCompletedNCT02632110Actinic keratosisTopical solution vehicle2DUSA Pharmaceuticals, Inc.CompletedNCT02438423InfluenzaInactivated influenza vaccine1Mark Prausnitz, Georgia Institute of TechnologyCompletedNCT02745392Acute migraineZP ZolmitriptanPlacebo23Zosano Pharma CorporationCompletedNCT03646188Basal cell carcinomaDoxorubicin-containing MNA1SkinJect, Inc.RecruitingNCT01049490Influenza infectionS-OIV H1N1 vaccineNADr. Ivan FN Hung, The University of Hong KongCompletedNCT03847610Healthy volunteersPhenoxymethyl penicillin1Imperial College LondonCompletedNCT02192021Cutaneous T cell lymphomaDoxorubicin (MNA-D)1Oleg E. Akilov, MD, PhD, University of PittsburghRecruitingNCT01304563InfluenzaTIV 2010/2011 influenza vaccineNAThe University of Hong KongCompletedNCT02837094Type 1 diabetesC19-A3 GNP1Cardiff UniversityActive, not recruitingNCT00558649Influenza, humanFlu vaccine (FLUARIX®)NANanoPass Technologies LtdCompletedNCT03126786Diabetic macular edemaIVT aflibercept, Sham SC, SC CLS-TA2Clearside Biomedical, Inc.CompletedNCT03097315Uveitis, posterior uveitis, anterior uveitis, intermediate panuveitisCLS-TA3Clearside Biomedical, Inc.CompletedNCT04053140Healthy volunteersPenicillin G1Imperial College LondonRecruitingTable 3Marketed microneedle-based transdermal productsBrand nameManufacturerDescriptionApplicationDarmaroller®Derma spark, CanadaMetallic microneedle arrayUsed to treat acne, stretch mark, hair loss. Able to enhance drug absorption (minoxidil, hyaluronic acid, etc.).MicroHyala®CosMED Pharmaceutical Co. Ltd., JapanDissolvable microneedle patchIt contains hyaluronic acid that is released in the skin to treat wrinkle.VaxMat®TheraJect Inc., USADissolvable microneedle patchIt is used to deliver macromolecules, like proteins, peptides, and vaccines.Micro-Trans®Valeritas Inc., USAMicroneedle patchIt delivers the drug into the dermis without limitations of drug size, structure, charge, or the patient's skin characteristics.Drugmat®TheraJect Inc., USADissolvable microneedle patchIt delivers hundreds of micrograms of drug rapidly through the stratum corneum into the epidermal tissue.Nanoject®Debiotech, SwitzerlandMicroneedle array-based deviceUseful for intradermal and hypodermic drug delivery and for interstitial fluid diagnosticsSoluvia®Becton Dickinson, USAHollow microneedle arrayIt is a prefillable microinjection system for accurate intradermal delivery of drugs and vaccines.IDflu®/Intanza®Sanofi Pasteur, Lyon, FranceIntradermal microneedle injectionPrefilled with influenza vaccine for intradermal influenza vaccination.Micronjet®NanoPass Inc., IsraelIntradermal microneedle injectionIt is used with any standard syringe for painless delivery of drugs, protein, and vaccines.Macroflux®Zosano Pharma Inc., USAMetallic microneedle arrayDelivery of peptides and vaccinesMicrocore®Corium International Inc., USADissolvable peptide microneedle patchDeliver small as well as large molecules, like proteins, peptides, and vaccines.Dermapen®Microneedle array-based deviceUsed for treating various conditions of skin, ranging from acne, stretch mark, and hair loss, and can enhance drug absorption.Microstructured transdermal patch3M Corp., USAHollow microneedle arrayIt delivers liquid formulations over a range of viscosities.Table 4List of patents on microneedle array technologies, fabrication of mold for the preparation of microneedles, and therapeutic drugs delivered by this technologyS. no.Key inventionPatent no.ApplicantDateReferenceA. Technologies based on microneedle array1Microneedle array and method of useUS10398885B23M Innovation Properties2016-1-19Michael J. et al. (2019)2Microneedle injection patch comprises a microneedle array connected to the injectionTW162907613BioFirst Corporation2017-01-12Jian Chang Jen (2018)3Hollow microneedle with bevel openingUS20160166819A13M Innovative Properties Company2014-07-10Simmers Patrick et al. (2016)4Hollow microneedle with beveled tipUS20160136406A13M Innovative Properties Company2013-07-10Berry Dennis (2016)5Assembly of a microneedle adhesive patch. The assembly can include a backing, an adhesive, and a matrix coupled to the backing.WO 20130960263M Innovative Properties Company2012-10-12Cantor and Stockholm (2013)B. Therapeutic moieties delivered transdermally by microneedle array1Method and device for the treatment of ocular diseases in human subject, comprises inserting a hollow microneedle into the eye.US2018002851641Clearside Biomedical Inc.2017-03-09Vladinir Zarnitsyn et al. (2018)2Rapidly dissolvable microneedle for the transdermal delivery of the therapeuticsWO2017011320A1University of North Carolina2016-07-08Desima Joseph, et al. (2017)3Formulations and method for the targeted ocular delivery of the therapeutic agents by intraocular microneedle patchUS20160310417A1Emory University, Georgia2014-12-19Mark R. et al. (2016)4Direct application system and method for the delivery of bioactive compositions and formulations by microneedle delivery technologyUS20160175408A1Aquavit Pharmaceuticals Inc.2014-08-04Sobin Chang et al. (2016)5Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the sameEP2785327A13M Innovative Properties2012-11-30Ying Zhang et al. (2014)C. Fabrication of mold for the casting of microneedles1Microneedle unit and microneedle assemblyEP309794241Toppan Printing Co., Ltd., Tokyo2015-1-22European Patent Application (2016)2Invention relates to for example a method for producing a microneedle array that can be administered into the bodyJP5931130132Japan2014-06-20Japanese Patent Application (2016)3Invention relates to a microneedle and manufacturing method of a mold for manufacturing of microneedleCN105025976AChina2014-1-21Chinese Patent (2015)4A metallic microneedle array, including substrate and a metal sheet fixed on the surface of the substrateCN 103263727Tsinghua University, China2013-5-22Yue and Wang (2013)5Microneedle, including forming A plurality of first-linear grooves on a substrate in parallel to one another along A first direction using grinding and forming a plurality of second-linear grooves on the substrate in parallel to one another in a second direction intersecting the first direction using grinding.US20130030374A1Toppan Printing Co., Ltd.2012-10-11Sugimura et al. (2013)6Invention relates to plastic microneedle strips that are used in TDD for increasing the DD rate through the skin.WO 2013066262Singapore2011-11-02Spain Lim et al. (2013)

Conclusion and Future Prospect {#Sec7}
==============================

From the last 15 years, the deportment toward enhancing transdermal delivery of larger peptide, protein, and vaccine compound as well as traditional molecules has led to the MN-based product development and their regulation becoming the area of key importance to the researcher working in this area. Globally, the arrival of various commercial MN products is highly anticipated. MN may extend a remarkable impact on clinical medicine over the upcoming future.
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